Semaglutide · source year
6 selected, source-linked Semaglutide records carrying a 2021 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
6 selected records.
3 represented types.
6 distinct public records.
Cited chronology
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03357380 at 2026-07-30T19:56:31.568Z. Its registry update date was 2021-11-22, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03611582 at 2026-07-30T19:56:31.576Z. Its registry update date was 2021-11-11, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Regulatory
The Federal Register published notice 2021-18072, attributed to FDA and its parent HHS department, on 2021-08-23. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Semaglutide.
Source: Federal Register via GovInfo ↗
Regulatory
DailyMed lists Structured Product Labeling version 1 for the reviewed Semaglutide label family with a published date of 2021-06-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory
The official Drugs@FDA dataset lists original submission 1 for NDA 215256 with status AP dated 2021-06-04, and names semaglutide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Safety
FDA's dated enforcement report D-0536-2021 lists Class II and source status Terminated for Cardinal Health Inc. PeptideScanner connects the report to reviewed application NDA213051 through exact openFDA application-number annotations.